<sup>18F</sup> Flutemetamol-PET Aided Classification of Cerebral Amyloid Angiopathy
Michele Romoli, Giulia Marinoni, Luca Tagliabue, Antonella Capozza, Federica Matteucci, Vincenzo Mattone, Marco Longoni, P. Cenni, Maria Ruggiero, Nicola Rifino, Isabella Canavero, Giorgio B. Boncoraglio, Mario Stanziano, Anna Bersano, Benedetta Storti
Abstract
OBJECTIVES: flutemetamol PET in reclassification and stratification of risk of bleeding in people with mixed CAA-arteriolosclerosis features. METHODS: flutemetamol PET imaging and were followed up for at least 1 year. We compared cases with CAA and arteriolosclerosis + CAA features and defined long-term outcomes (composite outcome including death, ICH, ischemic stroke, SAH, TFNE) depending on PET status (CAA/amyloid pathology vs arteriolosclerosis-predominant groups). RESULTS: = 0.04) compared with the arteriolosclerosis-predominant group. DISCUSSION: Flutemetamol PET imaging can help in reclassification of mixed arteriolosclerosis + CAA into CAA/amyloid pathology and arteriolosclerosis-predominant, with implications on long-term risk of recurrent events. CLASSIFICATION OF EVIDENCE: flutemetamol PET can distinguish between CAA + arteriolosclerosis and arteriolosclerosis-predominant pathology.